Morgan Dempsey Capital Management LLC Has $74,000 Stock Holdings in Electromed, Inc. (NYSE:ELMD)

Morgan Dempsey Capital Management LLC trimmed its stake in shares of Electromed, Inc. (NYSE:ELMD) by 63.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,498 shares of the company’s stock after selling 4,414 shares during the quarter. Morgan Dempsey Capital Management LLC’s holdings in Electromed were worth $74,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Ritholtz Wealth Management acquired a new position in Electromed in the 4th quarter valued at approximately $488,000. Barclays PLC acquired a new position in Electromed in the 3rd quarter valued at approximately $215,000. Navellier & Associates Inc. acquired a new position in Electromed in the 3rd quarter valued at approximately $368,000. State Street Corp increased its position in Electromed by 14.5% in the 3rd quarter. State Street Corp now owns 22,066 shares of the company’s stock valued at $474,000 after acquiring an additional 2,800 shares during the period. Finally, Walleye Capital LLC acquired a new position in Electromed in the 3rd quarter valued at approximately $274,000. 40.82% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have issued reports on ELMD shares. B. Riley started coverage on shares of Electromed in a research report on Thursday, February 20th. They issued a “buy” rating and a $38.00 price target for the company. StockNews.com cut shares of Electromed from a “strong-buy” rating to a “buy” rating in a research report on Thursday.

Insider Transactions at Electromed

In related news, Director Andrew Summers sold 50,751 shares of the stock in a transaction on Monday, February 24th. The shares were sold at an average price of $27.30, for a total transaction of $1,385,502.30. Following the transaction, the director now directly owns 65,714 shares of the company’s stock, valued at $1,793,992.20. This represents a 43.58 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Kathleen Skarvan sold 8,640 shares of the stock in a transaction on Friday, February 14th. The stock was sold at an average price of $32.25, for a total transaction of $278,640.00. Following the transaction, the director now directly owns 71,576 shares in the company, valued at approximately $2,308,326. This represents a 10.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 163,812 shares of company stock worth $4,728,773 over the last three months. 14.00% of the stock is owned by company insiders.

Electromed Stock Up 0.8 %

ELMD opened at $27.04 on Friday. Electromed, Inc. has a twelve month low of $13.74 and a twelve month high of $35.56. The company has a fifty day moving average of $31.33 and a 200-day moving average of $25.69. The stock has a market cap of $231.38 million, a PE ratio of 36.05 and a beta of 0.33.

Electromed Company Profile

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.